- Home
- CLLS vs IVA Comparison
CLLS vs IVA Comparison
Compare CLLS & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- IVA
- Stock Information
- Founded
- CLLS 1999
- IVA 2011
- Country
- CLLS France
- IVA France
- Employees
- CLLS N/A
- IVA N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- IVA Health Care
- Exchange
- CLLS Nasdaq
- IVA Nasdaq
- Market Cap
- CLLS 148.1M
- IVA 162.8M
- IPO Year
- CLLS 2007
- IVA 2020
- Fundamental
- Price
- CLLS $1.45
- IVA $3.36
- Analyst Decision
- CLLS Buy
- IVA Strong Buy
- Analyst Count
- CLLS 3
- IVA 4
- Target Price
- CLLS $7.00
- IVA $10.50
- AVG Volume (30 Days)
- CLLS 120.5K
- IVA 17.0K
- Earning Date
- CLLS 05-27-2025
- IVA 03-26-2025
- Dividend Yield
- CLLS N/A
- IVA N/A
- EPS Growth
- CLLS N/A
- IVA N/A
- EPS
- CLLS N/A
- IVA N/A
- Revenue
- CLLS $49,217,000.00
- IVA $14,591,573.00
- Revenue This Year
- CLLS $1.26
- IVA $18.05
- Revenue Next Year
- CLLS N/A
- IVA $46.74
- P/E Ratio
- CLLS N/A
- IVA N/A
- Revenue Growth
- CLLS 435.38
- IVA N/A
- 52 Week Low
- CLLS $1.10
- IVA $1.53
- 52 Week High
- CLLS $3.38
- IVA $3.90
- Technical
- Relative Strength Index (RSI)
- CLLS 60.38
- IVA 61.22
- Support Level
- CLLS $1.40
- IVA $2.88
- Resistance Level
- CLLS $1.56
- IVA $3.45
- Average True Range (ATR)
- CLLS 0.09
- IVA 0.26
- MACD
- CLLS 0.03
- IVA 0.03
- Stochastic Oscillator
- CLLS 76.09
- IVA 81.36
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.